Comparison of efficacy, safety and sedation between two doses of olanzapine in the control of chemotherapy-induced nausea and vomiting (CINV). A prospective, randomized, double-blind, controlled study was conducted, enrolling 68 patients receiving a single-day cycle of high and moderately emetogenic chemotherapy. Patients received either of olanzapine 5 mg or 10 mg from day 1 through 3 in addition to ondansetron and dexamethasone. Control of CINV, nausea, sedation, quality of life (QoL) and adverse events were compared. Nausea, emesis control and improvement of QoL were similar in both groups. Sedation severity was 133% higher with 10 mg olanzapine. Lower dose olanzapine is effective to control CINV with significantly reduced sedation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2217/fon-2020-0834 | DOI Listing |
Medicine (Baltimore)
January 2025
Department of Acupuncture and Moxibustion, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, P.R. China.
Rationale: Patients with extensive small cell lung cancer (SCLC) generally have a dismal survival rate and are conventionally treated with chemotherapy. This study aimed to explore an alternative treatment approach by combining traditional Chinese medicine (TCM) with radiotherapy and chemotherapy.
Patient Concerns: A 68-year-old male was diagnosed with extensive-stage SCLC.
J Oncol Pharm Pract
January 2025
Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.
Introduction: Data on the optimal management of patients with hematologic malignancies and chemotherapy-induced nausea and vomiting (CINV) are lacking, particularly for multiday chemotherapy regimens. We report our institutional experience in patients with B-cell lymphoma receiving multiday dose-adjusted R-EPOCH chemotherapy utilizing two CINV prophylaxis strategies.
Methods: We performed a retrospective, single-center, cohort study evaluating hospitalized patients with aggressive non-Hodgkin B-cell lymphoma receiving DA-R-EPOCH (April 2016 to October 2022).
Rev Med Suisse
January 2025
Centre de médecine intégrative et complémentaire, Service d'anesthésiologie, Centre hospitalier universitaire vaudois, 1011 Lausanne.
This article reports on new findings on integrative and complementary medicine published in 2024. The implementation of guidelines for the management of pain in cancer patients is discussed. Then, a literature review is presented, that aims to clarify the role of complementary approaches in the management of chemotherapy-induced nausea and vomiting and provides a concrete example of how recommendations are established.
View Article and Find Full Text PDFBMC Cancer
January 2025
The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.
Background: Chemotherapy-induced nausea and/or vomiting (CINV) is an intractable adverse effect of anticancer drugs. Although prophylactic use of fosaprepitant may be effective in reducing CINV, there is a lack of studies evaluating the application of fosaprepitant in real world.
Aims And Methods: This study prospectively observed the effectiveness and safety for the prophylaxis of CINV in a real-world clinical setting.
Complement Ther Med
January 2025
School of Nursing, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China. Electronic address:
Objective: To evaluate the efficacy of non-pharmacological interventions in improving chemotherapy induced delayed nausea and vomiting symptoms using a network meta-analysis.
Methods: Four Chinese databases (CNKI, Wanfang Data Knowledge Service Platform, VIP, Sinomed) and five English databases (PubMed, Cochrane Library, Embase, Web of Science, CINAHL) were searched from the establishment of the database to April 2024. A Bayesian network meta-analysis was performed on the response rate to the improvement of chemotherapy induced delayed nausea and vomiting, as well as improvement in KPS score, under different non-pharmacological interventions by using R 4.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!